The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

In recent days, Amazon Pharmacy announced it would begin offering Novo Nordisk’s Wegovy once-daily weight-loss pill through ...

Hims & Hers Health (HIMS) is back in focus as investors reassess its telehealth model, weighing GLP-1 related interest and ...

Hims & Hers Health, Inc. analysis: subscription health platform growth, GLP-1 risks, and catalysts in women’s health & ...

Hims & Hers Health, Inc. remains a Strong Buy as it is well-positioned to capitalize on secular wellness and digital health trends favored by younger generations. The company boasts stellar ...

The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that ...

Hims & Hers Health Stock Slides on Earnings Miss and Soft Guidance: Is $40 the Next Stop? Hims & Hers Health (HIMS) reported Q2 results after the close last night, delivering a mixed set of numbers ...

Hims & Hers posted record revenue this quarter. It is still selling patented weight loss drugs on its platform and is now getting sued by the pharmaceutical companies. Investors would do best to avoid ...

Hims & Hers, the high-flying telehealth company that rapidly ascended from a buzzy startup selling Viagra to a multibillion-dollar business with a Super Bowl ad, had a hard week. The San Francisco ...

Hims & Hers Health Inc. HIMS shares are trading lower Tuesday after GoodRx Inc. GDRX announced a collaboration with Novo Nordisk to provide discounted access to two of the most in-demand GLP-1 drugs, ...

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results ...